Dova Pharmaceuticals, Inc, a pharmaceutical company, focuses on acquiring, developing, and commercializing drug candidates for thrombocytopenia disease. The company's lead product candidate is DOPTELET that is indicated for the treatment of thrombocytopenia in adult patients with chronic liver disease scheduled to undergo a procedure. It also develops DOPTELET for the treatment of chronic immune thrombocytopenia and chemotherapy-induced thrombocytopenia.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone919-748-5975
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$10.35 million
Profitability
Miscellaneous
Employees115
Next Earnings Date11/14/2019 (Estimated)
OptionableOptionable
Dova Pharmaceuticals (NASDAQ:DOVA) Frequently Asked Questions
What is Dova Pharmaceuticals' stock symbol?
Dova Pharmaceuticals trades on the NASDAQ under the ticker symbol "DOVA."
How were Dova Pharmaceuticals' earnings last quarter?
Dova Pharmaceuticals Inc (NASDAQ:DOVA) released its quarterly earnings results on Tuesday, August, 6th. The company reported ($0.60) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.57) by $0.03. The company had revenue of $3.52 million for the quarter, compared to analyst estimates of $5.63 million. Dova Pharmaceuticals had a negative net margin of 544.09% and a negative return on equity of 101.60%. View Dova Pharmaceuticals' Earnings History.
When is Dova Pharmaceuticals' next earnings date?
What price target have analysts set for DOVA?
7 brokerages have issued 1-year target prices for Dova Pharmaceuticals' stock. Their predictions range from $15.00 to $44.00. On average, they expect Dova Pharmaceuticals' stock price to reach $27.8571 in the next year. This suggests a possible upside of 91.9% from the stock's current price. View Analyst Price Targets for Dova Pharmaceuticals.
What is the consensus analysts' recommendation for Dova Pharmaceuticals?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Dova Pharmaceuticals in the last year. There are currently 1 sell rating, 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Dova Pharmaceuticals.
What are Wall Street analysts saying about Dova Pharmaceuticals stock?
Here are some recent quotes from research analysts about Dova Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Dova Pharmaceuticals, Inc. is a pharmaceutical company. It focuses on acquiring, developing and commercializing drug candidates for thrombocytopenia diseases. The company's drug candidate includes avatrombopag, an orally administered thrombopoietin receptor agonist which are in clinical stage. Dova Pharmaceuticals, Inc. is based in Durham, North Carolina. " (8/15/2019)
- 2. HC Wainwright analysts commented, "Valuation and risks to price target achievement. We maintain our Buy rating and $18 price target. Our valuation is based on our clinical net present value (NPV) model, which allows us to flex multiple assumptions affecting a drug’s potential commercial profile. Our valuation is currently based on the opportunity for avatrombopag in the CLD, cITP, and CIT indications broken down as follows: (1) CLD contributes 61.1% of our valuation ($206 million peak sales projection in the U.S.); (2) cITP contributes 31.8% of our valuation ($174 million peak sales projection in the U.S." (4/26/2019)
Has Dova Pharmaceuticals been receiving favorable news coverage?
News headlines about DOVA stock have been trending negative this week, InfoTrie Sentiment Analysis reports. The research firm identifies positive and negative media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Dova Pharmaceuticals earned a media sentiment score of -2.3 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View News Stories for Dova Pharmaceuticals.
Are investors shorting Dova Pharmaceuticals?
Dova Pharmaceuticals saw a drop in short interest in the month of July. As of July 31st, there was short interest totalling 3,420,600 shares, a drop of 12.3% from the June 30th total of 3,898,400 shares. Based on an average daily trading volume, of 387,100 shares, the short-interest ratio is presently 8.8 days. Approximately 28.2% of the shares of the company are short sold. View Dova Pharmaceuticals' Current Options Chain.
Who are some of Dova Pharmaceuticals' key competitors?
Some companies that are related to Dova Pharmaceuticals include Apellis Pharmaceuticals (APLS), Prestige Consumer Healthcare (PBH), Nabriva Therapeutics (NBRV), Pacira Biosciences (PCRX), Tricida (TCDA), Corcept Therapeutics (CORT), Eidos Therapeutics (EIDX), Deciphera Pharmaceuticals (DCPH), Supernus Pharmaceuticals (SUPN), G1 Therapeutics (GTHX), Enanta Pharmaceuticals (ENTA), Turning Point Therapeutics (TPTX), Aimmune Therapeutics (AIMT), AnaptysBio (ANAB) and Insmed (INSM).
What other stocks do shareholders of Dova Pharmaceuticals own?
Who are Dova Pharmaceuticals' key executives?
Dova Pharmaceuticals' management team includes the folowing people:
- Dr. David S. Zaccardelli, Pres & CEO (Age 54)
- Mr. Mark W. Hahn, CFO & Sec. (Age 56)
- Mr. Kevin Laliberte, Sr. VP of Product Devel. (Age 41)
- Mr. Jason Levine, VP of Marketing
- Mr. Ilija Zlatar, Head of U.S. Sales
When did Dova Pharmaceuticals IPO?
(DOVA) raised $66 million in an IPO on Thursday, June 29th 2017. The company issued 4,100,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan, Jefferies and Leerink Partners served as the underwriters for the IPO.
Who are Dova Pharmaceuticals' major shareholders?
Dova Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional investors include Perceptive Advisors LLC (12.34%), BlackRock Inc. (3.47%), Vanguard Group Inc. (2.40%), Sanders Morris Harris LLC (1.85%), Morgan Stanley (1.13%) and GW&K Investment Management LLC (0.58%). Company insiders that own Dova Pharmaceuticals stock include Alex Sapir, David Zaccardelli, Jason Hoitt, Kevin Laliberte, Lee F Md Phd Allen, Life Sciences Maste Perceptive, Mark W Hahn, Paul B Manning, Roger Jeffs and Steven M Goldman. View Institutional Ownership Trends for Dova Pharmaceuticals.
Which major investors are selling Dova Pharmaceuticals stock?
DOVA stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Wells Fargo & Company MN, Bank of New York Mellon Corp, Northern Trust Corp, GW&K Investment Management LLC and JPMorgan Chase & Co.. Company insiders that have sold Dova Pharmaceuticals company stock in the last year include David Zaccardelli, Jason Hoitt, Kevin Laliberte, Lee F Md Phd Allen, Mark W Hahn and Roger Jeffs. View Insider Buying and Selling for Dova Pharmaceuticals.
Which major investors are buying Dova Pharmaceuticals stock?
DOVA stock was purchased by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, Sanders Morris Harris LLC, Vanguard Group Inc., Morgan Stanley, Sio Capital Management LLC, Renaissance Technologies LLC, SG Americas Securities LLC and Paloma Partners Management Co. Company insiders that have bought Dova Pharmaceuticals stock in the last two years include Alex Sapir, David Zaccardelli, Life Sciences Maste Perceptive, Paul B Manning and Steven M Goldman. View Insider Buying and Selling for Dova Pharmaceuticals.
How do I buy shares of Dova Pharmaceuticals?
Shares of DOVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Dova Pharmaceuticals' stock price today?
One share of DOVA stock can currently be purchased for approximately $14.52.
How big of a company is Dova Pharmaceuticals?
Dova Pharmaceuticals has a market capitalization of $418.18 million and generates $10.35 million in revenue each year. The company earns $-72,280,000.00 in net income (profit) each year or ($2.60) on an earnings per share basis. Dova Pharmaceuticals employs 115 workers across the globe.View Additional Information About Dova Pharmaceuticals.
What is Dova Pharmaceuticals' official website?
How can I contact Dova Pharmaceuticals?
Dova Pharmaceuticals' mailing address is 240 Leigh Farm Road Suite 245, Durham NC, 27707. The company can be reached via phone at 919-748-5975 or via email at [email protected]
MarketBeat Community Rating for Dova Pharmaceuticals (NASDAQ DOVA)
MarketBeat's community ratings are surveys of what our community members think about Dova Pharmaceuticals and other stocks. Vote "Outperform" if you believe DOVA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DOVA will underperform the S&P 500 over the long term. You may vote once every thirty days.
